The neoantigen field is had a pivotal year with a surge of new investments, collaborations and positive clinical readouts such as those by Nykode Therapeutics & Regeneron & Transgene & NEC’s. However, key challenges remain before they truly become blockbuster therapies for patients in need.

Building upon the momentum and progress in the field, such as the announcement of the first British patient to be receiving an mRNA-based cancer therapy, the 7th International Neoantigen Summit 2024 returned to Amsterdam to unite the international neoantigen community to overcome neoantigen identification, prediction, and translational challenges that are holding back the full potential of this class of therapies.

Leading neoantigen trailblazers from the likes of Gritstone Bio, CureVac, Medigene, Geneos Therapeutics & Nykode Therapeutics came together at the only end to end, industry dedicated neoantigen meeting covering the depth and breadth of the field from mRNA- to DNA- and viral vector- based vaccines as well as novel cell therapies with the true potentials to develop safe, durable and effective off-the-shelf or individualized neoantigen immunotherapeutics and vaccines for cancer patients.